Rabbit Polyclonal ASS1 antibody. Suitable for WB, IHC-P, ICC/IF, Flow Cyt (Intra) and reacts with Mouse, Human samples. Immunogen corresponding to Synthetic Peptide within Human ASS1 aa 150-250 conjugated to Keyhole Limpet Haemocyanin.
pH: 7.4
Preservative: 0.09% Sodium azide
Constituents: 99% PBS
WB | IHC-P | ICC/IF | Flow Cyt (Intra) | |
---|---|---|---|---|
Human | Tested | Tested | Tested | Tested |
Mouse | Tested | Expected | Expected | Expected |
Rat | Predicted | Predicted | Predicted | Predicted |
Cow | Predicted | Predicted | Predicted | Predicted |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info 1/1000 | Notes - |
Species Human | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat, Cow | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/75 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat, Cow | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/10 - 1/50 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat, Cow | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes ab171870 - Rabbit polyclonal IgG, is suitable for use as an isotype control with this antibody. |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat, Cow | Dilution info - | Notes - |
Select an associated product type
One of the enzymes of the urea cycle, the metabolic pathway transforming neurotoxic amonia produced by protein catabolism into inocuous urea in the liver of ureotelic animals. Catalyzes the formation of arginosuccinate from aspartate, citrulline and ATP and together with ASL it is responsible for the biosynthesis of arginine in most body tissues.
ASS, ASS1, Argininosuccinate synthase, Citrulline--aspartate ligase
Rabbit Polyclonal ASS1 antibody. Suitable for WB, IHC-P, ICC/IF, Flow Cyt (Intra) and reacts with Mouse, Human samples. Immunogen corresponding to Synthetic Peptide within Human ASS1 aa 150-250 conjugated to Keyhole Limpet Haemocyanin.
pH: 7.4
Preservative: 0.09% Sodium azide
Constituents: 99% PBS
ASS1 or argininosuccinate synthase 1 is an enzyme that plays an important role in the urea cycle. It catalyzes the conversion of citrulline and aspartate into argininosuccinate using ATP in the process. The ASS1 protein is commonly expressed in the liver where it actively participates in the detoxification of ammonia. It has a molecular mass of approximately 46 kDa. Some alternate names for this protein include ASS and ASS-1.
Argininosuccinate synthase 1 contributes significantly to the synthesis of arginine an essential amino acid through its conversion activities. The enzyme operates as a homotrimer a complex consisting of three identical subunits. This enzymatic activity is indispensable in maintaining the balance of nitrogen and ammonia within the body particularly important for liver and kidney functions.
ASS1 is a critical component of both the urea cycle and the nitric oxide metabolism pathway. The urea cycle helps in detoxifying ammonia by converting it into urea which is excreted in urine. In nitric oxide metabolism ASS1 links with nitric oxide synthase to facilitate the use of arginine in producing nitric oxide a vital signaling molecule. The pathway engagement partners include proteins like citrin which supplies aspartate for the reaction.
ASS1 has implications in citrullinemia and hepatocellular carcinoma. Citrullinemia results from mutations in the ASS1 gene leading to defective urea cycle function and ammonia accumulation. In cancer particularly hepatocellular carcinoma low expression of ASS1 correlates with poor prognosis as cancer cells often exhibit arginine auxotrophy. Connections through these conditions involve interactions with enzymes such as arginase which also influences arginine availability.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
All lanes: Western blot - Anti-ASS1 antibody (ab191165) at 1/1000 dilution
All lanes: HeLa cell lysate at 35 µg
Predicted band size: 47 kDa
All lanes: Western blot - Anti-ASS1 antibody (ab191165) at 1/1000 dilution
All lanes: Mouse kidney tissue lysate at 35 µg
Predicted band size: 47 kDa
Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human kidney tissue labeling ASS1 with ab191165 at 1/75 dilution.
Intracellular flow cytometric analysis of WiDr cells labeling ASS1 with ab191165 at 1/10 dilution (lower histogram) compared to a negative control cell (top histogram). FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.
Immunofluorescent analysis of HeLa cells labeling ASS1 with ab191165 at 1/10 dilution followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green). DAPI was used to stain the cell nuclear (blue).
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com